Multi-omics analysis of core E3 ubiquitin ligase identifies prognostic biomarkers associated with immune infiltration and drug sensitivity in lung adenocarcinoma

被引:0
|
作者
Shi, Yuan-Xiang [1 ]
Wang, Jia [1 ]
Jiang, Zhen-Lin [2 ]
Yan, Jian-Hua [2 ]
机构
[1] Hunan Normal Univ, Hunan Prov Peoples Hosp, Affiliated Hosp 1, Inst Clin Med, Changsha, Peoples R China
[2] Hunan Normal Univ, Hunan Prov Peoples Hosp, Affiliated Hosp 1, Dept Cardiac Thorac Surg, Changsha, Peoples R China
来源
JOURNAL OF CANCER | 2025年 / 16卷 / 04期
基金
中国国家自然科学基金;
关键词
ubiquitin ligases; Lung cancer; Prognosis; Immune infiltration; Drug sensitivity; GENE-EXPRESSION; FAMILY;
D O I
10.7150/jca.104837
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ubiquitination is involved in several tumor immunomodulatory processes, and targeting E3 ubiquitin ligases has substantial potential in cancer therapy. Methods: In this study, the key E3 ubiquitin ligases involved in regulating the malignant progression of LUAD were studied. We first systematically investigated the expression landscape, prognosis, immune infiltration, drug sensitivity, and potential molecular mechanisms of these hub genes in LUAD. CDC20 was localized by immunofluorescence analysis in tumor cell lines, and its expression level was determined by immunohistochemistry on tissue chips. Single-cell analysis and spatial transcriptomics were used to determine CDC20 expression in multiple cell types. Molecular docking was performed via computer simulation to verify the ability of drugs to bind to target genes. Results: We found that these hub genes are specifically overexpressed in LUAD and are associated with poor patient prognosis. All five E3 ubiquitin ligase genes were negatively correlated with B cells and dendritic cells but positively related to neutrophil immune infiltration. In addition, analysis of the CTRP and GDSC databases revealed that the sensitivity to multiple antitumor drugs increased when CCNF was highly expressed. GSEA enrichment analysis demonstrated that the G2M_CHECKPOINT, MTORC1_SIGNALING, OXIDATIVE_PHOSPHORYLATION, and GLYCOLYSIS signaling pathways were enriched when CDC20 was highly expressed. Further correlation analysis indicated that CDC20 was positively correlated with the expression of the key genes mTOR, S6K1, and 4E-BP1 and the autophagy-related gene ULK1 in the mTORC1 signaling pathway. Conclusions: These key E3 ubiquitin ligases serve as potential molecular biomarkers for predicting the prognosis, immune response, and drug sensitivity of LUAD patients.
引用
收藏
页码:1363 / 1378
页数:16
相关论文
共 24 条
  • [11] Multi-omics profiling and experimental verification of tertiary lymphoid structure-related genes: molecular subgroups, immune infiltration, and prognostic implications in lung adenocarcinoma
    Wu, Sixuan
    Pan, Junfan
    Pan, Qihong
    Zeng, Lijun
    Liang, Renji
    Li, Yuehua
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [12] Pan-cancer analysis identifies CDCA3 as a novel prognostic marker associated with immune infiltration in lung adenocarcinoma through bioinformatics analysis
    Yang, Hao
    Wei, Xueqiang
    Zhang, Liren
    Xiang, Li
    Wang, Ping
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2902 - 2916
  • [13] Pan-cancer analysis identifies DDX56 as a prognostic biomarker associated with immune infiltration and drug sensitivity
    Ruan, Zhaohui
    Zhang, Yuetong
    Quan, Qi
    Jiang, Jiaxin
    Wang, Qianyu
    Zhang, Yujing
    Peng, Roujun
    FRONTIERS IN GENETICS, 2022, 13
  • [14] A multi-omic screening approach identifies the E3-ubiquitin ligase DCAF13 as a novel vulnerability in lung adenocarcinoma
    Wagner, Vinona T.
    Chang, Yun-Chien
    Giansanti, Piero
    Ollinger, Rupert
    Engleitner, Thomas
    Kuster, Bernhard
    Bassermann, Florian
    CANCER RESEARCH, 2023, 83 (07)
  • [15] Spatio-temporal multi-omics analysis of lung tissue and matched biofluids identifies circulatory safety biomarkers for monitoring inhaled drug induced lung injury
    Majumder, M. M.
    Williams, E.
    Lindvall, M. O.
    Jarnuczak, A.
    Hamm, G.
    Di Poto, C.
    Iannetta, A. A.
    Touza, J. L.
    Allman, E. L.
    Miele, E.
    Lindgren, J.
    Sand, E.
    Setyo, L.
    Anderberg, R.
    Oag, S.
    Costyson, A.
    Keith, B.
    Tan, J.
    Aberg, P.
    Jones, S.
    Cairns, J.
    Fitzpatrick, P.
    Johansson, J.
    Hess, S.
    Hornberg, J.
    Terillon, S.
    Ostridge, K.
    Mohorianu, I.
    Ollerstam, A.
    TOXICOLOGY LETTERS, 2024, 399 : S168 - S168
  • [16] Integrating machine learning and multi-omics analysis to develop an asparagine metabolism immunity index for improving clinical outcome and drug sensitivity in lung adenocarcinoma
    Li, Chunhong
    Mao, Yuhua
    Hu, Jiahua
    Su, Chunchun
    Li, Mengqin
    Tan, Haiyin
    IMMUNOLOGIC RESEARCH, 2024, : 1447 - 1469
  • [17] Integrative Analysis of Multi-Omics Data-Identified Key Genes With KLRC3 as the Core in a Gene Regulatory Network Related to Immune Phenotypes in Lung Adenocarcinoma
    Mao, Kai
    Zhao, Yunxi
    Ding, Bo
    Feng, Peng
    Li, Zhenqing
    Zhou, You Lang
    Xue, Qun
    FRONTIERS IN GENETICS, 2022, 13
  • [18] Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells
    Zhang, Ye
    Qu, Xiujuan
    Hu, Xuejun
    Yang, Xianghong
    Hou, Kezuo
    Teng, Yuee
    Zhang, Jingdong
    Sada, Kiyonao
    Liu, Yunpeng
    JOURNAL OF PATHOLOGY, 2009, 218 (02): : 248 - 255
  • [19] Identification of E3 ubiquitin ligase-associated prognostic genes and construction of a prediction model for uterine cervical cancer based on bioinformatics analysis
    Yan, Zhengchao
    Yu, Jingwei
    Wang, Shuyuan
    Wen, Weibo
    Xin, Mengyuan
    Li, Xiangdan
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [20] E3 ubiquitin ligase FBXW11 as a novel inflammatory biomarker is associated with immune infiltration and NF-icB pathway activation in pancreatitis and pancreatic cancer
    Tan, Peng
    Cai, Shuang
    Huang, Zhiwei
    Li, Mo
    Liu, Shenglu
    Chen, Jiatong
    Fu, Wenguang
    Zhao, Lingyu
    CELLULAR SIGNALLING, 2024, 116